FOXO1 enhances CAR T cell stemness, metabolic fitness and efficacy
Jack D. Chan(The University of Melbourne), Phillip K. Darcy(Peter MacCallum Cancer Centre), Kah Min Yap(The University of Melbourne), Ian A. Parish(The University of Melbourne), Yukuan Huang(The University of Melbourne), Emily B. Derrick(The University of Melbourne), Jane Oliaro(The University of Melbourne), Nicole Y. L. Saw(The University of Melbourne), Christian Deo T. Deguit(The University of Melbourne), Jasmine Li(The University of Melbourne), Emma V. Petley(The University of Melbourne), Paul J. Neeson(The University of Melbourne), Kirsten L. Todd(The University of Melbourne), Junyun Lai(The University of Melbourne), Joe Jiang Zhu(Zhejiang University), Benjamin Solomon(Peter MacCallum Cancer Centre), Joan So(The University of Melbourne), Lev M. Kats(Beth Israel Deaconess Medical Center), Kevin Sek(The University of Melbourne), Dat Quoc Nguyen(The University of Melbourne), Paul A. Beavis(Peter MacCallum Cancer Centre), Kylie M. Quinn(Monash University), Imran G. House(The University of Melbourne), Junming Tong(The University of Melbourne), Andrew M. Scott(Olivia Newton-John Cancer Wellness & Research Centre), Isabelle Munoz(The University of Melbourne), Amanda X. Y. Chen(Peter MacCallum Cancer Centre), Clare Y. Slaney(The University of Melbourne), Cheok Weng Chan(The University of Melbourne), Maria N. de Menezes(The University of Melbourne), Jiawen Li(The University of Melbourne), Joelle S. Kim(The University of Melbourne), Simon J. Harrison(Peter MacCallum Cancer Centre), Phoebe Dunbar(The University of Melbourne), Thang X. Hoang(The University of Melbourne), P. Leung(RMIT University), Joel N. Lee(The University of Melbourne), C. Scheffler(The University of Melbourne)
Cited by 213
Related Papers
Crizotinib versus Chemotherapy in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2013|3.4k
First-Line Crizotinib versus Chemotherapy in <i>ALK</i>-Positive Lung Cancer
|New England Journal of Medicine|2014|3.2k
First-Line Lorlatinib or Crizotinib in Advanced <i>ALK</i> -Positive Lung Cancer
|New England Journal of Medicine|2020|1.1k
Efficacy of Selpercatinib in <i>RET</i> Fusion–Positive Non–Small-Cell Lung Cancer
|New England Journal of Medicine|2020|835